Canada-based Concordia International Corp. said it appointed Frances Cloud to its board of directors, effective Nov. 1.

Cloud has worked in the pharmaceutical sector over 20 years, having served as an analyst and investment banker for companies including Nomura International, IMI Securities and Swiss Bank Corp., according to a news release.

She founded consulting firm Pharmacloud Research in 2009, to cover the generic drug industry in Europe, India and the Middle East and North Africa region.

Cloud's expertise in the European pharmaceutical industry will help the Concordia buy targeted products and companies and expand its product portfolio, said Concordia CEO Graeme Duncan.

Concordia International, a specialty pharmaceutical company, plans to change its name to Advanz Pharma following a recapitalization.